The main objective of this Project is to study the role of the lipogenic pathway and Rho GTPases in lung and pancreatic cancer with the ultimate goal of improving patient survival by using a multidisciplinary approach, focused in these two pathways that are likely to be universally altered in cancer and that are mechanistically linked.
These discoveries will lead to the identification of novel therapeutic targets, novel markers of resistance to standard treatments, to the design of adequate combinatorial treatments, and to better assays to establish diagnosis and prognosis that will allow the development of novel targeted and personalized therapies.
These challenging objectives will be reached through the specialized knowledge of the Consortium of a set of genes, involved in phospholipid metabolism, including upstream regulators such as Rho GTPases and their effectors (defined as the “CANCERALIA” selected genes)
CANCERALIA is a projected cofounded by the European Commission’s Seventh Framework Programme for Research and Technological Development (2007-2013).
The overall European contribution to the Project is 2.996.808,80 €